A Phase 1b/2 Multicenter Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated Unresectable Stage IIIb-IV Melanoma
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to find out more about talimogene laherparepvec, in people with advanced melanoma when given in combination with another drug called ipilimumab.
Description
The purpose of this study is to evaluate the safety of talimogene laherparepvec in combination with ipilimumab and to evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.
Details
| Condition | Melanoma |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX3392 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.